AIM - AIM ImmunoTech Engages Business Development Firm Azenova LLC to Catalyze Partnering Development and Commercialization Efforts for Ampligen® Pipeline Programs | Benzinga
OCALA, Fla., Oct. 17, 2023 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE:AIM) ("AIM") today announced it has entered into an agreement with Azenova, LLC ("Azenova"), a professional business development (BD) consulting firm, to support efforts to partner AIM's pipeline programs with a particular focus on the company's lead asset, Ampligen®, for the treatment of various malignant solid tumors.
Azenova has been engaged to assist AIM with its BD efforts with the goal of entering into a partnership, out-license or other transaction whereby a biopharmaceutical company takes on the further development and commercialization of Ampligen® with the goal of maximizing value to AIM. This process may not result in any transaction and the company does not intend to disclose additional details unless and until it has entered into a definitive agreement.
"With our growing body of compelling clinical data, we believe Ampligen® has significant potential to provide a therapeutic solution for a wide range of cancers, immune disorders and viral diseases. We believe the timing of our engagement with Azenova perfectly aligns their BD ...